Company intelligence / Profile preview

AIO-YMO

Ownership: Private
Development stage: Other

Overview

AIO-YMO is a biotechnology company focused on the development of novel small molecule inhibitors for oncology indications. The company's lead program, also designated as AIO-YMO, is a potent and selective inhibitor of Indoleamine 2,3-dioxygenase 1 (IDO1), an enzyme that plays a critical role in tumor-mediated immunosuppression. By inhibiting IDO1, the therapy aims to restore the immune system's ability to recognize and destroy cancer cells. Currently in the pre-clinical stage, the company is advancing its research to support future clinical trials in patients with various solid tumors.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on AIO-YMO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIO-YMO.

Explore the full profile